CLEOPATRA - Roche's pertuzumab to queen it over HER2 breast cancer?
This article was originally published in Scrip
Roche will make global regulatory filings for its novel HER2-targeting anticancer pertuzumab by the end of the year on the basis of new data from the CLEOPATRA study. The pivotal Phase III trial met its primary endpoint of progression-free survival, top-line data announced today show.
You may also be interested in...
Circassia is returning the US rights to two COPD drugs to AstraZeneca as it admits it cannot meet its debt payments from the deal.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.